

Laurus Labs

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	LAURUS IN
Equity Shares (m)	540
M.Cap.(INRb)/(USDb)	1212.5 / 12.7
52-Week Range (INR)	2245 / 913
1, 6, 12 Rel. Per (%)	12/108/145
12M Avg Val (INR M)	2999

Financials & valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	68.1	87.7	103.6
EBITDA	18.0	28.5	33.2
Adj. PAT	9.0	16.1	19.0
EBIT Margin (%)	19.4	26.3	25.8
Cons. Adj. EPS (INR)	16.8	30.0	35.2
EPS Gr. (%)	189.4	78.4	17.5
BV/Sh. (INR)	100.8	126.1	155.8

Ratios

Net D:E	0.4	0.4	0.2
RoE (%)	18.0	26.4	25.0
RoCE (%)	13.5	19.4	18.9
Payout (%)	15.6	15.6	15.6

Valuations

P/E (x)	133.7	74.9	63.7
EV/EBITDA (x)	68.6	43.5	37.1
Div. Yield (%)	0.1	0.2	0.2
FCF Yield (%)	1.0	-0.3	2.0
EV/Sales (x)	18.1	14.1	11.9

Shareholding pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	27.5	27.5	27.6
DII	11.9	13.7	11.7
FII	30.8	28.0	26.2
Others	29.8	30.8	34.5

FII includes depository receipts

CMP: INR2,244 TP: INR2,830 (+26%) Buy

Beats estimates; CDMO keeps raising the bar

Strong CDMO pipeline and peptides lift estimates ~30%

- LAURUS delivered slightly better-than-expected revenue in 2QFY27, though EBITDA/PAT significantly beat our estimates by 22%/38%. A favorable segmental mix and currency benefits boosted margins for the quarter.
- Laurus continues to break its earlier quarterly record in CDMO segment, backed by late-stage clinical projects, commercial API supplies and scale-up of new assets.
- Particularly, in Peptide segment, Laurus has operationalized a large-scale manufacturing facility ahead of schedule. It is also capturing the entire value chain in terms of pre-clinical to commercial supplies (comprising multiple steps of manufacturing followed by purification and isolation).
- Laurus continues to work on launching new products, adding new markets and sustaining efficient supply chain management despite global political turmoil.
- We raise our earnings estimates by 28%/30% for FY27/FY28, factoring in a) the scale-up of its CDMO segment, including peptide manufacturing, b) a steady uptick in affordable medicine supply, and 3) a better segmental mix. Considering the demand outlook, LAURUS' readiness to meet large innovator customer needs and improved return ratios, we value LAURUS at 74x 12-month forward earnings to arrive at a TP of INR2,830. Reiterate BUY.

Strong mix and operating leverage boost profitability

- 2Q revenue grew 33.4% YoY to INR22.1b (our est. INR21.1b), driven by robust CDMO growth and stable affordable medicine business (led by FDF).
- Gross margin (GM) expanded by 315bp YoY to 63% due to a better divisional mix.
- EBITDA margin expanded by ~960bp YoY to 34% (our est: 29.1%). Other expenses/staff costs decreased 550bp/100bp YoY.
- EBITDA grew 86% YoY to INR7.5b (our est. INR6.1b).
- Adj PAT grew 128% YoY to INR4.4b (our est: INR3.2b).
- For 1H FY27, revenue/EBITDA/PAT grew 31%/77%/128% YoY to INR42b/INR13.9b/INR8.1b.

CDMO/FDF lead the growth pack

- Synthesis business (40% of sales, small molecules) rose 86% YoY to INR8.7b.
- FDF sales grew 31% YoY to INR6.8b (31% of sales).
- API sales (28% of sales) grew 1% YoY to INR6.3b.
- Bio division sales (1% of sales) fell 39% YoY to INR290m.

Highlights from the management commentary

- CDMO business has no significant customer inventory build-up or anticipated de-stocking event from its customers.
- Peptide commercial revenue is expected around CY29, reflecting the regulatory validation and approval timelines; existing programs are at various stages of development, scale-up and validation.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Vipul Mehta (Vipul.Mehta@MotilalOswal.com) | **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- The peptide validation batch size is almost similar to commercial batch size for the contracts with LAURUS.
- Peptide resin contributes ~10-20% of peptide raw material costs, depending on fragment length.
- LAURUS expects to participate meaningfully in the GLP-1 peptide opportunity over the next five years, supported by its planned capacity and capabilities.
- Laurus Bio's LB4 facility is expected to be qualified in 3QFY27, followed by trials in 4QFY27; commercial supplies may begin in 1QFY28.
- The KRKA formulation facility remains on track, with Phase 1 production blocks and validation batches expected to commence in mid-2027; meaningful revenue contribution is expected from FY28/FY29 onwards

Consolidated- Quarterly Earning Model

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	vs Est
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	(%)
Net Sales	15,696	16,535	17,783	18,116	20,263	22,064	22,185	23,160	68,129	87,673	21,139	4.4
YoY Change (%)	31.4	35.1	25.7	5.3	29.1	33.4	24.8	27.8	22.7	28.7	27.8	
EBITDA	3,821	4,033	4,885	5,247	6,383	7,503	7,166	7,411	17,986	28,463	6,152	22.0
YoY Change (%)	123.2	126.1	71.3	24.8	67.0	86.1	46.7	41.2	70.4	58.2	52.5	
Margins (%)	24.3	24.4	27.5	29.0	31.5	34.0	32.3	32.0	26.4	32.5	29.1	
Depreciation	1,168	1,205	1,206	1,221	1,239	1,274	1,425	1,487	4,801	5,424	1,425	
Interest	515	400	388	404	422	441	466	466	1,707	1,795	466	
Other Income	104	270	58	118	92	130	77	77	550	375	73	
PBT before EO expense	2,242	2,697	3,349	3,740	4,814	5,918	5,352	5,535	12,028	21,618	4,333	
Extra-Ord expense	0	0	83	126	0	0	0	0	209	0	0	
PBT	2,242	2,697	3,266	3,614	4,814	5,918	5,352	5,535	11,819	21,618	4,333	
Tax	631	760	735	795	1,194	1,551	1,365	1,411	2,920	5,521	1,105	
Rate (%)	28.2	28.2	22.5	22.0	24.8	26.2	25.5	25.5	24.7	25.5	25.5	
Minority Interest & P/L of Asso. Cos.	7	-3	10	28	-56	-47	30	30	-1	-44	30	
Reported PAT	1,603	1,940	2,521	2,791	3,676	4,415	3,957	4,093	8,899	16,141	3,198	
Adj PAT	1,603	1,940	2,585	2,890	3,676	4,415	3,957	4,093	9,019	16,141	3,198	38.0
YoY Change (%)	1,164.5	877.9	180.1	53.9	129.3	127.6	53.1	41.6	188.5	79.0	64.8	
Margins (%)	10.2	11.7	14.5	16.0	18.1	20.0	17.8	17.7	13.2	18.4	15.1	

KPIs - Consolidated	FY26				FY27E				FY26	FY27E	FY27
INRb	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2Q
API	6.4	6.2	7.2	7.7	6.5	6.3	7.1	7.7	27.5	27.6	7.3
YoY Change (%)	(4.1)	10.8	35.6	12.5	2.7	1.3	(0.9)	(0.1)	22.7	28.7	18.6
Custom Synthesis	4.9	4.7	4.1	5.2	8.4	8.8	8.6	8.4	19.0	34.1	7.9
YoY Change (%)	130.4	57.5	2.0	13.7	69.4	85.8	110.0	60.0	38.0	79.6	68.0
Formulation	4.1	5.2	6.1	4.5	5.0	6.8	6.1	6.5	19.9	24.4	5.3
YoY Change (%)	50.0	57.9	39.2	(17.1)	22.1	30.7	0.0	45.1	25.6	22.8	3.1
Cost Break-up											
RM Cost (% of Sales)	40.6	40.1	39.1	38.6	37.3	37.0	37.2	37.3	39.6	37.2	38.5
Staff Cost (% of Sales)	13.7	13.0	12.4	12.3	12.8	12.0	12.5	12.2	12.8	12.4	13.0
R&D Expenses(% of Sales)	4.1	3.9	3.9	3.6	4.1	2.9	3.1	2.8	2.5	1.9	3.1
Other Cost (% of Sales)	21.4	22.5	21.0	20.1	18.4	17.0	18.0	18.5	21.2	18.0	19.4
Gross Margins(%)	59.4	59.9	60.9	61.4	62.7	63.0	62.8	62.7	60.4	62.8	61.5
EBITDA Margins(%)	24.3	24.4	27.5	29.0	31.5	34.0	32.3	32.0	26.4	32.5	29.1
EBIT Margins(%)	16.9	17.1	20.7	22.2	25.4	28.2	25.9	25.6	19.4	26.3	22.4



Other highlights from the management commentary

- Affordable medicines revenue is expected to continue growing in upcoming quarters, supported by product registrations across multiple countries; API pricing has stabilized despite geopolitical pressure.
- Reiterated gross margin/EBITDA margin guidance of ~60%+/30%+ for FY27.
- Reiterated capex guidance of ~INR30b over FY27 and FY28, a majority of growth capex is directed towards APIs.
- LAURUS aims for medium-term asset turnover of 1.1x, in line with its six-year average vs. a historical peak of 1.4x; improvement will depend on project maturity and ramp-up of recently commissioned capacities.
- Net debt was ~INR24b, while a net debt-to-EBITDA improved to 1.02x from 1.28x supported by internal cash generation.
- Acquisition of a 60% stake in Canada-based Galenvs Sciences for ~USD3.75m, strengthening its oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) based diagnostics/therapeutics CRO-CDMO capabilities.
- Acquisition of a 52% stake in SI & C Resins for ~INR323.5m; specializing in manufacturing and supply of high-quality polymer and silica-based products for chemical, pharmaceutical, biotechnology industries.
- R&D was INR650m (~3% of revenue) for the quarter.

Key exhibits

Exhibit 1: Revenue grew 33.4% YoY in 2QFY27




Exhibit 2: Share of FDF/API stood at 31%/28% in 2QFY27




Exhibit 3: API sales flat YoY




Exhibit 4: FDF sales rose 31% YoY






Exhibit 5: Gross margin expanded 315bp YoY



Source: MOFSL, Company

Exhibit 6: EBITDA margin expanded 960bp YoY



Source: MOFSL, Company

CDMO fuels growth; generics remain steady

CDMO - Late-stage pipeline support growth momentum

- CDMO (Small Molecules) revenue grew 77% YoY to INR17.1b in 1HFY27, driven by advancing late-stage clinical projects, commercial API supplies and ramp-up of new assets.
- Stable demand for complex and integrated small-molecule offerings continues to support CDMO growth, with the pipeline expanding across high-quality molecules, multiple technologies and therapeutic indications.
- Laurus commissioned its Vizag peptide manufacturing facility with >16,000L SPPS capacity and is further expanding capacity to cater to growing customer requirements.
- Multiple large-scale API capacity projects in Vizag are progressing well, supporting the company's ability to scale up commercial CDMO opportunities.
- The expanding pipeline across modalities and indications, coupled with increasing customer requirements, provides healthy medium-term visibility for the CDMO business.
- Capacity expansion across peptides and APIs positions LAURUS well to capture larger opportunities as projects progress from clinical to commercial stages.
- We expect the CDMO business to deliver 50.4% CAGR over FY26-28, supported by the commercialization of late-stage projects, diversified customers, with increasing contribution from complex modalities.

Generics - FDF drives growth, while API business remains resilient

- Generics revenue grew 13% YoY to INR24.6b in 1HFY27, supported by continued growth in the formulations business.
- FDF revenue increased 15% YoY to INR13b, driven by order-book growth, stable volumes and pricing resilience across ARV and US portfolio, while API revenue grew 2% YoY to INR12.8b.
- The business maintained a healthy order book and consistent execution despite ongoing global supply chain challenges.
- Potential new launches/integrated CMO engagements and ramping product registration across EM drive healthy outlook.
- The KRKA JV formulation facility is progressing as planned, with Phase I production blocks expected to open in mid-2027, focused on high-potency and general OSD capabilities.
- Regulatory filings continued steadily, with cumulative filings reaching 92 DMFs and 96 developed-market FDF dossiers, supporting future launches.
- We expect the Generics business to deliver 11.4% CAGR over FY26-28, driven by new product launches and increasing penetration across regulated and emerging markets.

Bio - Building capabilities across fermentation, advanced therapies


- Bio revenue declined 16% YoY to INR640m in 2QFY27, due to campaign phasing rather than any underlying weakness in pipeline momentum.
- LAURUS is strengthening long-term strategic partnerships with key customers across AOF/CDMO to support steady growth and anchor capacity utilization.
- It is expanding application of enzymatic technologies across clinical and commercial API projects, enhancing the integrated CDMO offering.
- LB-4 fermentation facility (>400kL) is progressing as planned, with commissioning targeted for 3QFY27; customer discussions on capacity reservations are advancing.
- The gradual ramp-up of fermentation assets is expected to improve capacity utilization over time, although the pace will depend on customer qualification and commercial program conversion.
- We expect the Bio business to clock a 2.6% CAGR over FY26-28 to INR1.9b

Valuation and view

- We raise our earnings estimates by 28%/30% for FY27/FY28, factoring in a) a scale-up of its CDMO segment, including peptide manufacturing, b) a steady uptick in affordable medicine supply, and 3) a better segmental mix.
- Considering the demand outlook, LAURUS' readiness to meet large innovator customer needs and improved return ratios, we value LAURUS at 74x 12-month forward earnings to arrive at a TP of INR2,830. Reiterate BUY.


Story in charts

Exhibit 7: Expect a sales CAGR of 23% over FY26-28




Source: MOFSL, Company

Exhibit 8: Synthesis contribution to increase




Source: MOFSL, Company

Exhibit 9: EBITDA CAGR to be 36% over FY26-28




Source: MOFSL, Company

Exhibit 10: Expect a strong EPS trajectory over FY26-28




Source: MOFSL, Company

Exhibit 11: Return ratios to surge over FY26-28



Source: MOFSL, Company

Exhibit 12: Capex intensity to improve by FY28



Source: MOFSL, Company

Financials and valuations

Income Statement							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	49,356	60,406	50,408	55,540	68,129	87,673	103,598
Change (%)	2.5	22.4	-16.6	10.2	22.7	28.7	18.2
Total Expenditure	35,131	44,483	42,633	44,987	50,143	59,210	70,366
% of Sales	71.2	73.6	84.6	81.0	73.6	67.5	67.9
EBITDA	14,224	15,923	7,775	10,553	17,986	28,463	33,233
Margin (%)	28.8	26.4	15.4	19.0	26.4	32.5	32.1
Depreciation	2,515	3,241	3,846	4,301	4,801	5,424	6,468
EBIT	11,709	12,682	3,929	6,252	13,185	23,039	26,765
Int. and Finance Charges	1,024	1,652	1,829	2,160	1,707	1,795	1,756
Other Income	153	60	263	163	550	375	414
PBT bef. EO Exp.	10,839	11,090	2,364	4,254	12,028	21,618	25,423
EO Items	0	0	0	589	-209	0	0
PBT after EO Exp.	10,839	11,090	2,364	4,843	11,818	21,618	25,423
Total Tax	2,514	3,123	684	1,299	2,920	5,521	6,330
Tax Rate (%)	23.2	28.2	28.9	26.8	24.7	25.5	24.9
Minority Interest	2	32	55	-23	11	-44	120
Reported PAT	8,322	7,965	1,625	3,567	8,887	16,141	18,972
Adjusted PAT	8,322	7,965	1,625	3,126	9,046	16,141	18,972
Change (%)	-15.4	-4.3	-79.6	92.4	189.4	78.4	17.5
Margin (%)	16.9	13.2	3.2	5.6	13.3	18.4	18.3

Consolidated - Balance Sheet							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	1,075	1,077	1,077	1,077	1,080	1,080	1,080
Total Reserves	32,437	39,298	40,032	43,647	51,921	65,542	81,551
minority interest	79	111	46	1,300	1,313	1,313	1,313
Net Worth	33,591	40,487	41,155	46,024	54,313	67,934	83,944
Minority Interest	0	0	0	0	0	0	0
Total Loans	17,320	21,006	26,115	27,553	25,185	32,185	31,685
Deferred Tax Liabilities	691	825	570	319	294	294	294
Capital Employed	51,602	62,317	67,842	73,895	79,792	100,413	115,922
Gross Block	35,283	46,085	54,745	61,378	68,652	83,839	97,276
Less: Accum. Deprn.	11,221	14,462	18,308	22,609	27,409	32,833	39,302
Net Fixed Assets	24,062	31,623	36,437	38,769	41,243	51,005	57,974
Goodwill on Consolidation	2,463	2,463	2,463	2,463	2,463	2,463	2,463
Capital WIP	8,132	5,508	4,228	4,584	7,733	10,547	7,109
Total Investments	308	993	1,714	2,819	3,093	3,093	3,093
Curr. Assets, Loans&Adv.	34,715	36,017	39,028	44,721	50,580	63,402	80,939
Inventory	17,603	16,848	18,454	19,365	23,422	26,604	31,809
Account Receivables	13,542	15,804	16,629	20,072	21,550	28,343	33,776
Cash and Bank Balance	759	485	1,417	1,442	1,137	2,701	8,555
Loans and Advances	2,811	2,880	2,528	3,842	4,471	5,754	6,799
Curr. Liability & Prov.	18,079	14,287	16,029	19,459	25,320	30,097	35,656
Account Payables	8,764	7,107	10,512	9,585	12,521	13,626	16,194
Other Current Liabilities	7,753	6,165	4,334	8,520	11,099	14,283	16,878
Provisions	1,562	1,016	1,183	1,354	1,700	2,187	2,585
Net Current Assets	16,637	21,730	22,999	25,262	25,260	33,305	45,283
Appl. of Funds	51,602	62,317	67,842	73,896	79,792	100,413	115,922

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)							
EPS	15.5	14.8	3.0	5.8	16.8	30.0	35.2
Cash EPS	20.1	20.8	10.2	13.8	25.7	40.0	47.2
BV/Share	62.4	75.2	76.4	85.4	100.8	126.1	155.8
DPS	2.0	1.9	0.4	0.9	2.1	3.9	4.6
Payout (%)	15.6	15.6	15.6	15.6	15.6	15.6	15.6
Valuation (x)							
P/E	145.3	151.8	744.2	386.8	133.7	74.9	63.7
Cash P/E	111.6	107.9	221.0	162.8	87.3	56.1	47.5
P/BV	36.0	29.9	29.4	26.3	22.3	17.8	14.4
EV/Sales	24.8	20.4	24.5	22.2	18.1	14.1	11.9
EV/EBITDA	86.2	77.2	158.7	117.1	68.6	43.5	37.1
Return Ratios (%)							
RoE	27.9	21.5	4.0	7.2	18.0	26.4	25.0
RoCE	20.1	16.3	4.6	6.7	13.5	19.4	18.9
RoIC	23.0	18.6	4.8	7.3	14.9	22.6	22.2
Working Capital Ratios							
Fixed Asset Turnover (x)	1.4	1.3	0.9	0.9	1.0	1.0	1.1
Asset Turnover (x)	1.0	1.0	0.7	0.8	0.9	0.9	0.9
Inventory (Days)	130	102	134	127	125	111	112
Debtor (Days)	100	95	120	132	115	118	119
Creditor (Days)	65	43	76	63	67	57	57
Leverage Ratio (x)							
Current Ratio	1.9	2.5	2.4	2.3	2.0	2.1	2.3
Interest Cover Ratio	11.4	7.7	2.1	2.9	7.7	12.8	15.2
Net Debt/Equity	0.5	0.5	0.6	0.5	0.4	0.4	0.2

Consolidated - Cash Flow Statement

(InRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	10,839	11,089	2,364	4,843	11,819	21,618	25,423
Depreciation	2,515	3,241	3,846	4,301	4,801	5,424	6,468
Interest & Finance Charges	862	1,455	1,750	2,100	1,649	1,420	1,342
Direct Taxes Paid	-1,823	-2,855	-1,046	-1,375	-2,939	-5,521	-6,330
(Inc)/Dec in WC	-3,416	-3,153	-332	-2,814	251	-6,481	-6,124
CF from Operations	8,977	9,778	6,581	7,055	15,580	16,462	20,779
Others	135	161	33	-106	655	0	0
CF from Operating incl EO	9,111	9,939	6,615	6,949	16,235	16,462	20,779
(Inc)/Dec in FA	-8,767	-9,875	-7,476	-5,411	-10,631	-18,000	-10,000
Free Cash Flow	344	64	-862	1,538	5,604	-1,538	10,779
(Pur)/Sale of Investments	-393	-223	-800	-1,054	-757	0	0
Others	17	137	52	-352	502	375	414
CF from Investments	-9,143	-9,961	-8,224	-6,817	-10,887	-17,625	-9,586
Issue of Shares	43	74	26	102	200	0	0
Inc/(Dec) in Debt	1,968	2,138	5,078	1,561	-3,301	7,000	-500
Interest Paid	-850	-1,404	-1,743	-2,092	-1,707	-1,795	-1,756
Dividend Paid	-859	-1,075	-862	-431	-863	-2,521	-2,963
Others	5	13	43	753	422	42	-122
CF from Fin. Activity	307	-253	2,541	-107	-5,249	2,725	-5,341
Inc/Dec of Cash	275	-275	932	25	99	1,562	5,852
Opening Balance	483	757	482	1,415	1,442	1,543	3,107
Total Cash and Cash equivalent	759	485	1,417	1,442	1,137	2,701	8,555

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.